Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

帕唑帕尼 医学 安慰剂 软组织肉瘤 软组织 肉瘤 调色板(绘画) 内科学 临床试验 肿瘤科 放射科 癌症 病理 舒尼替尼 计算机科学 替代医学 操作系统
作者
Winette T.A. van der Graaf,Jean‐Yves Blay,Sant P. Chawla,Dong‐Wan Kim,B. Bui-Nguyen,Paolo G. Casali,Patrick Schöffski,Massimo Aglietta,Arthur P. Staddon,Yasuo Beppu,Axel Le Cesne,Hans Gelderblom,Ian Judson,Nobuhito Araki,M. Ouali,Sandrine Marréaud,Rachel Hodge,Mohammed R Dewji,Corneel Coens,George D. Demetri
出处
期刊:The Lancet [Elsevier BV]
卷期号:379 (9829): 1879-1886 被引量:2100
标识
DOI:10.1016/s0140-6736(12)60651-5
摘要

Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.This phase 3 study was done in 72 institutions, across 13 countries. Patients with angiogenesis inhibitor-naive, metastatic soft-tissue sarcoma, progressing despite previous standard chemotherapy, were randomly assigned by an interactive voice randomisation system in a 2:1 ratio in permuted blocks (with block sizes of six) to receive either pazopanib 800 mg once daily or placebo, with no subsequent cross-over. Patients, investigators who gave the treatment, those assessing outcomes, and those who did the analysis were masked to the allocation. The primary endpoint was progression-free survival. Efficacy analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00753688.372 patients were registered and 369 were randomly assigned to receive pazopanib (n=246) or placebo (n=123). Median progression-free survival was 4·6 months (95% CI 3·7-4·8) for pazopanib compared with 1·6 months (0·9-1·8) for placebo (hazard ratio [HR] 0·31, 95% CI 0·24-0·40; p<0·0001). Overall survival was 12·5 months (10·6-14·8) with pazopanib versus 10·7 months (8·7-12·8) with placebo (HR 0·86, 0·67-1·11; p=0·25). The most common adverse events were fatigue (60 in the placebo group [49%] vs 155 in the pazopanib group [65%]), diarrhoea (20 [16%] vs 138 [58%]), nausea (34 [28%] vs 129 [54%]), weight loss (25 [20%] vs 115 [48%]), and hypertension (8 [7%] vs 99 [41%]). The median relative dose intensity was 100% for placebo and 96% for pazopanib.Pazopanib is a new treatment option for patients with metastatic non-adipocytic soft-tissue sarcoma after previous chemotherapy.GlaxoSmithKline.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
1秒前
DW的应助被light采纳,获得10
2秒前
3秒前
yy完成签到,获得积分10
4秒前
水煮电吹风的应助被xw采纳,获得15
4秒前
方卓发布了新的文献求助10
4秒前
4秒前
5秒前
5秒前
Maestro_S的应助被wang采纳,获得10
5秒前
labor的应助被Code_king采纳,获得10
5秒前
labor的应助被Code_king采纳,获得10
5秒前
上官若男的应助被Code_king采纳,获得10
5秒前
Pursue。完成签到,获得积分10
6秒前
西哥完成签到,获得积分10
6秒前
6秒前
7秒前
luo0504完成签到 ,获得积分10
7秒前
butterflycat完成签到,获得积分10
7秒前
zz发布了新的文献求助10
8秒前
8秒前
tz发布了新的文献求助10
9秒前
在水一方的应助被sm采纳,获得10
9秒前
Akim的应助被wyr采纳,获得10
10秒前
90发布了新的文献求助10
10秒前
勤奋的花卷完成签到 ,获得积分10
12秒前
ddw发布了新的文献求助10
13秒前
灵机完成签到,获得积分10
13秒前
lml发布了新的文献求助10
14秒前
无名发布了新的文献求助10
14秒前
欣慰灵珊发布了新的文献求助10
14秒前
zzx发布了新的文献求助10
15秒前
16秒前
慕青的应助被云阁无语姐采纳,获得10
16秒前
19秒前
20秒前
20秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177404
求助须知:如何正确求助?哪些是违规求助? 9568297
关于积分的说明 21798595
捐赠科研通 7772027
什么是DOI,文献DOI怎么找? 3432346
关于科研通互助平台的介绍 2556564
邀请新用户注册赠送积分活动 2477863